About Novogyne

Novogyne Pharmaceuticals is a joint venture between Novartis Pharmaceuticals Corporation and Noven Pharmaceuticals, Inc. Since May 1998, Novogyne has been offering pharmaceutical products that enable physicians to better serve the medical needs of mature women. Novogyne's products include Vivelle-Dot® (estradiol transdermal system), the #1 prescribed estrogen patch* and the smallest estrogen patch available, and CombiPatch® (estradiol/norethindrone acetate transdermal system). With these advanced patches, Novogyne was the first company in the U.S. offering transdermal systems for both the estrogen-only and combination estrogen/progestin markets.

What Do We Offer You?

With the mature woman’s comfort in mind, Novogyne offers the most advanced—and wearable—transdermal patches on the market:

  • Vivelle-Dot, a postage-stamp–sized advanced generation estrogen patch and the smallest estrogen patch available.
  • CombiPatch, the first combination estrogen/progestin hormone therapy (HT) patch in the U.S.

The Novogyne Advantage

Novogyne's transdermal systems deliver drugs utilizing an adhesive patch containing medication. When adhered to the skin, medication is delivered through the tissues and into the bloodstream over an extended period of time. Novogyne's patches utilize the patented Delivery Optimized Thermodynamics (DOT) Matrix® technology, which allows them to deliver more drug through a smaller patch area than any other HT patches. DOT Matrix achieves this without compromising the patch's ability to adhere. DOT Matrix patches adhere to the skin through normal activities, including showering, swimming, and exercise.

For more information on the DOT Matrix technology, click here.

DOT Matrix® is a registered trademark of Noven Pharmaceuticals, Inc.

The information contained within this Web site is appropriate for U.S. residents only.

*IMS Health®, National Prescription Audit Plus™, June 2011.

CombiPatch ISI CombiPatch ISI CombiPatch ISI Full Prescribing Information for CombiPatch www.fda.gov/medwatch Full Prescribing Information for CombiPatch www.fda.gov/medwatch Full Prescribing Information for CombiPatch www.fda.gov/medwatch
Vivelle-Dot ISI Vivelle-Dot ISI Vivelle-Dot ISI Full Prescribing Information for Vivelle-Dot www.fda.gov/medwatch Full Prescribing Information for Vivelle-Dot www.fda.gov/medwatch Full Prescribing Information for Vivelle-Dot www.fda.gov/medwatch
Indication and Important Safety Information for CombiPatch Indication and Important Safety Information for Vivelle-Dot

DOT Matrix® is a registered trademark of Noven Pharmaceuticals, Inc.

Close X
Leaving the CombiPatch® Web Site

You are now leaving the CombiPatch Web site and moving to an external Web site independently operated and not managed by Novogyne Pharmaceuticals. Novogyne assumes no responsibility for the content of the site.

Continue
Close X
Leaving the CombiPatch® Web Site

You are now leaving the CombiPatch Web site and moving to an external Web site operated by Noven Pharmaceuticals, Inc., a partner with Novartis Pharmaceuticals Corporation in the joint venture Novogyne Pharmaceuticals.

Continue
Close X
Leaving the CombiPatch® Web Site

You are now leaving the CombiPatch Web site and moving to an external Web site operated by Novartis Pharmaceuticals Corporation, a partner with Noven Pharmaceuticals, Inc. in the joint venture Novogyne Pharmaceuticals.

Continue